This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Zogenix Launches Improved Migraine Toolbox In Conjunction With National Migraine Awareness Month

SAN DIEGO, June 25, 2013 (GLOBE NEWSWIRE) -- In conjunction with National Migraine Awareness Month and in recognition of the significant unmet needs of migraine sufferers, Zogenix, Inc. (Nasdaq:ZGNX) is launching a new and improved SUMAVEL ® DosePro ® Migraine Toolbox to support patient education and empowerment. The Migraine Toolbox highlights the importance of having the appropriate medication on hand in the patient's "treatment toolbox" to address the specific migraine attack the patient is experiencing.

Dr. Stephen Silberstein, Professor and Director of the Jefferson Headache Center at Thomas Jefferson University, Philadelphia, Pennsylvania, said, "The frequency, intensity and speed of onset of migraines can vary greatly for patients so it is vital that migraine sufferers follow U.S. Headache Consortium Migraine treatment guidelines which recommend having access to a toolbox of treatment options. This includes medication such as oral and injectable triptan therapies that are fast-acting, convenient and easy-to use for more aggressive migraine attacks. In addition, education regarding treatment options is a key component of every migraine patient's treatment plan."

The Migraine Toolbox reinforces the role of SUMAVEL® DosePro® Needle-free Delivery System (sumatriptan injection) in treating specific types of migraine attacks such as those that cause patients to wake up or throw up, or require a fast-acting backup plan when migraines come on suddenly or recur. A National Headache Foundation survey of 500 migraine sufferers found that the majority of sufferers (54 percent) said their prescription oral migraine medication is not useful for every migraine attack, yet less than 20 percent of such sufferers use backup prescribed medication when an oral tablet is not an option. 1

Roger L. Hawley, chief executive officer of Zogenix, said, "Migraine is more than a headache. The Migraine Toolbox has become a standard part of migraine care in physician offices across the country where they are using the national migraine treatment guidelines to enhance outcomes.  The patient focus is on attack-based care which empowers the patient to select the appropriate form of triptan treatment based on the severity, symptoms and circumstances of that specific attack.  While oral triptans can often be the right choice, many patients have specific attacks where they know their oral medication may not give the pain-free outcome they need to be functional.  The Toolbox has become an excellent education resource for migraine suffers and for these physicians who follow the treatment guidelines. Our goal is to keep making the Migraine Toolbox better based on customer feedback."

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.19 -1.04%
FB $118.06 0.54%
GOOG $695.70 0.48%
TSLA $222.56 -4.20%
YHOO $36.00 -0.03%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs